MedTrace Logo

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2021-04-26

Study results available
· View outcomes & findings →

Summary

Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.

Conditions

  • Progressive Keratoconus

Interventions

DRUG

riboflavin ophthalmic solution

riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)

DEVICE

UVA Irradiation

UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Peter Hersh, MD · Cornea and Laser Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647699 on ClinicalTrials.gov